Akoya Biosciences Appoints Marilee Moy as Chief People Officer

2 years ago

Ms. Moy brings 30 years of HR leadership experience at high-performing companies Marilee Moy Marilee Moy, Chief People Officer, Akoya…

Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference

2 years ago

– Live video webcast presentation on Wednesday, January 26th at 9:00 AM ET CHARLESTON, S.C., Jan. 20, 2022 (GLOBE NEWSWIRE)…

First Patient Dosed in IntelGenx’s Resumed ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

2 years ago

SAINT LAURENT, Quebec, Jan. 20, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”), a leader in…

Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials

2 years ago

CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel…

NGM Bio to Participate in Upcoming Investor Conferences

2 years ago

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company…

BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease

2 years ago

RENO, Nev., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing…

AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium

2 years ago

First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first…

Origin Therapeutics Portfolio Company Posts Strong 2021 Following Successful Miami Conference

2 years ago

Microdose Psychedelic Insights’ Wonderland: Miami conference was the largest in-person conference in the psychedelic medicine business.Vancouver, British Columbia, Jan. 20,…

Chimerix to Present at B. Riley Virtual Oncology Conference

2 years ago

DURHAM, N.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that…

HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects of Chemotherapy Regimens

2 years ago

Preclinical Data for HCW 9218 Included in Pivotal Scientific Paper Published in Molecular TherapyMIRAMAR, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE)…